Logo

FDA: Stephen Hahn

Nov 01, 2019

Stephen Hahn is expected to be nominated as commissioner of the US Food and Drug Administration by President Trump, the White House said on Nov. 1. Hahn has been the chief medical executive at the MD Anderson Cancer Center since 2018 and a professor of radiation oncology at MD Anderson since 2015. Previously, he was chair of the Department of Radiation Oncology at the University of Pennsylvania, and before that, he was a senior investigator at the National Cancer Institute. Hahn holds a medical degree from Temple University and a BA in biology from Rice University. Following his appointment, Ned Sharpless, current acting commissioner of the FDA, will return to his post as director of the NCI, and Doug Lowy, who took over for Sharpless, will return to be principal deputy director of the NCI.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.